Chugai Gets Japanese Approval For Actemra For Rheumatoid Arthritis
This article was originally published in PharmAsia News
Japan's Chugai Pharmaceutical has received approval to market its Actemra (tocilizumab) antibody drug for treating rheumatoid arthritis in addition to its original indication for Castleman's disease. The approval is expected to be made official in April and the company expects to begin marketing it to the more than 700,000 people in Japan with rheumatoid arthritis. Chugai expects the drug to be a blockbuster, generating $44.5 million in sales in 2008. The firm also is teaming with Roche Holding to market the drug in Europe and North America. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - The U.S. FDA's Arthritis Advisory Committee voted 10 to one for approving Actemra (tocilizumab) a rheumatoid arthritis treatment that Japan's Chugai Pharmaceutical already is marketing for Castleman's disease, Chugai and partner Roche announced July 30
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
SINGAPORE - Chugai attributes the success of its development program for the novel interleukin-6 receptor-inhibiting Actemra (tocilizumab) to its partnership with Roche, Chugai Business Development General Manager Kimio Nishimura told Biomedical Asia 2008 attendees in Singapore April 16
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.